Press release
Myasthenia Gravis Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
Curious about the latest updates in the Myasthenia Gravis Pipeline? @ [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myasthenia Gravis Pipeline Report
* On Apri 28, 2026- Harbour BioMed (Guangzhou) Co. Ltd. initiated a study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.
* On April 27, 2026- argenx announced a study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to
* On April 24, 2026- Novartis Pharmaceuticals conducted a phase III study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
* On April 24, 2026- UCB Biopharma SRL announced a study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged greater than or equal to 2 to
* On April 22, 2026- Immunovant Sciences GmbH a phase 3 study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis
* DelveInsight's Myasthenia Gravis Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Myasthenia Gravis treatment.
* The leading Myasthenia Gravis Companies such as Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
* Promising Myasthenia Gravis Therapies such as NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
Want to know which companies are leading innovation in Myasthenia Gravis? @ Myasthenia Gravis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myasthenia Gravis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Myasthenia Gravis Pipeline Report also highlights the unmet needs with respect to the Myasthenia Gravis.
Myasthenia Gravis Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body's immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.
Myasthenia Gravis Emerging Drugs Profile
* IMVT-1402: Immunovant/ Roivant Sciences
IMVT-1402 is a next-generation, SC administered anti-FcRn mAb developed by Immunovant for the treatment of IgG-mediated autoimmune diseases. It effectively lowers pathogenic IgG while preserving normal albumin and cholesterol levels, mitigating safety issues seen with previous FcRn inhibitors. IMVT-1402 is positioned as Immunovant's lead asset and is advancing through clinical trials for conditions such as myasthenia gravis and other autoimmune disorders. Immunovant has strategically opted not to pursue regulatory approval for batoclimab in the indications of myasthenia gravis. Instead, the company aims to capitalize on insights gained from batoclimab clinical studies to guide and expedite the development of its next-generation program, IMVT-1402. Currently, the drug is in Phase III stage of its clinical development for the treatment of Myasthenia Gravis.
* KYV-101: Kyverna Therapeutics
KYV-101 is an autologous, fully human anti-CD19 CAR T-cell therapy developed by Kyverna Therapeutics to treat B cell-driven autoimmune diseases such as generalized myasthenia gravis (gMG). It works by engineering a patient's own T cells to target and eliminate CD19-positive B cells, thereby reducing autoantibody production and potentially "resetting" the immune system. The therapy aims to provide long-lasting remission with a single infusion rather than chronic immunosuppression. Currently, the therapy is being evaluated under Phase II/III stage of its development for the treatment of Myasthenia gravis.
* CABA-201: Cabaletta Bio
Resecabtagene autoleucel (CABA-201) is an autologous, fully human anti-CD19 CAR T-cell therapy developed by Cabaletta Bio for treating B cell-mediated autoimmune diseases such as generalized myasthenia gravis (gMG). It works by reprogramming a patient's own T cells to target and eliminate CD19-positive B cells, aiming to remove autoreactive B cells that produce pathogenic antibodies. This deep B-cell depletion may reset the immune system and induce long-term remission. Currently, the drug is in Phase I/II stage of development for the treatment of Myasthenia Gravis.
If you're tracking ongoing Myasthenia Gravis Clinical trials, this press release is a must-read @ Myasthenia Gravis Treatment Drugs [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myasthenia Gravis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.
* Myasthenia Gravis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.
Myasthenia Gravis Companies
Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
Myasthenia Gravis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Myasthenia Gravis Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Myasthenia Gravis Pipeline Report covers it all @ Myasthenia Gravis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myasthenia Gravis Pipeline Report
* Coverage- Global
* Myasthenia Gravis Companies- Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
* Myasthenia Gravis Therapies- NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
* Myasthenia Gravis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myasthenia Gravis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what's next for the Myasthenia Gravis Treatment landscape in this detailed analysis @ Myasthenia Gravis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Myasthenia Gravis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myasthenia Gravis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KYV-101: Kyverna Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CABA-201: Cabaletta Bio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Myasthenia Gravis Key Companies
* Myasthenia Gravis Key Products
* Myasthenia Gravis- Unmet Needs
* Myasthenia Gravis- Market Drivers and Barriers
* Myasthenia Gravis- Future Perspectives and Conclusion
* Myasthenia Gravis Analyst Views
* Myasthenia Gravis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myasthenia-gravis-clinical-trial-pipeline-shows-potential-with-active-contributions-from-25-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myasthenia Gravis Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight here
News-ID: 4495902 • Views: …
More Releases from ABNewswire
Tenosynovial Giant Cell Tumors Clinical Trial Pipeline Accelerates as 5+ Pharma …
DelveInsight's, "Tenosynovial Giant Cell Tumors Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Tenosynovial Giant Cell Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Non-Alcoholic Steatohepatitis Pipeline Set for Transformational Expansion by 202 …
Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others
The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering a pivotal phase of innovation and clinical acceleration, driven by an expanding pipeline and increasing scientific understanding of disease biology. Companies such as Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, and Haisco Pharmaceutical Group are at the forefront of reshaping the future of NASH treatment…
STAT Inhibitors Pipeline Set for Breakthrough Innovation by 2026 with 22+ Therap …
Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others
The STAT inhibitors therapeutic landscape is undergoing a significant transformation, driven by rapid scientific advancements and increasing clinical activity across oncology and immunology indications. Companies such as Tvardi Therapeutics, Kymera Therapeutics, Inc., Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Inc., Purple Biotech, LEO Pharma A/S, JW Pharmaceutical,…
Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ …
Leading diabetic neuropathy companies include Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., AlgoTherapeutix, Tris Pharma, Inc., JMackem Co., Ltd, Lexicon Pharmaceuticals, Merz Pharmaceuticals GmbH, and others are evaluating new diabetic neuropathy drugs to improve the treatment landscape.
The Diabetic Neuropathy therapeutic landscape is undergoing a transformative shift, driven by increasing research investments and a strong pipeline of innovative therapies. Companies such as Vertex Pharmaceuticals Incorporated, Lexicon Pharmaceuticals, Trevena, Novo Nordisk…
More Releases for Myasthenia
Myasthenia Gravis (MG) Treatment Market: Insights and Trends
The Global Myasthenia Gravis (MG) Treatment Market is experiencing notable growth, driven by increasing awareness of the disease and advancements in treatment options. Myasthenia Gravis is a chronic autoimmune disorder that leads to varying degrees of muscle weakness, and effective management is crucial for improving patient quality of life.
With ongoing research and development in treatment modalities, the market is poised for significant expansion over the coming years.
Market Size and Growth:
The…
Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/
Medication Segment to Dominate the Myasthenia…
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC @…
